ASCO GUIDELINES Bundle

Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Brain Metastases

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475439

Contents of this Issue

Navigation

Page 8 of 9

a Aer consultation with a MDT. b Upfront systemic therapy can be discussed for select cases. Prognosis Prior WBRT or SRS Type of recurrence? Type of recurrence? Patients who have received prior treatment Favorable prognosis Prior SRS Yes, symptomatic mass effect Diffuse recurrence Diffuse recurrence WBRT-M/ HA, trial of systemic therapy, clinical trial, or BSC A trial of systemic therapy, clinical trial, repeat reduced dose WBRT-M, or BSC Repeat SRS, surgery, WBRT-M/ HA, trial of systemic therapy, or clinical trial SRS, surgery, trial of systemic therapy, or clinical trial/ other palliative options WBRT/M-HA Limited recurrence Limited recurrence Prior WBRT Poor prognosis

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Brain Metastases